Glucotrack, Inc. Files 8-K with Corporate Updates
Ticker: GCTK · Form: 8-K · Filed: Feb 4, 2025 · CIK: 1506983
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
Glucotrack filed an 8-K with corporate updates, including amendments and financial statements.
AI Summary
Glucotrack, Inc. filed an 8-K on February 4, 2025, reporting an amendment to its Articles of Incorporation or Bylaws, a Regulation FD disclosure, and other events. The filing also includes financial statements and exhibits. The company, formerly known as Integrity Applications, Inc., is incorporated in Delaware and has its fiscal year end on December 31.
Why It Matters
This filing indicates potential changes in Glucotrack's corporate structure or governance, which could impact its operations and investor relations.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain significant negative news.
Key Players & Entities
- Glucotrack, Inc. (company) — Registrant
- Integrity Applications, Inc. (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
- February 3, 2025 (date) — Earliest event reported
- February 4, 2025 (date) — Date of report
FAQ
What specific amendments were made to Glucotrack, Inc.'s Articles of Incorporation or Bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the summary text.
What is the nature of the Regulation FD disclosure mentioned in the filing?
The filing mentions a Regulation FD disclosure, but the content of this disclosure is not detailed in the provided text.
What are the key financial highlights from the included financial statements?
The filing states that financial statements and exhibits are included, but specific financial figures or highlights are not present in the provided text.
When did Glucotrack, Inc. change its name from Integrity Applications, Inc.?
The filing indicates the name change from Integrity Applications, Inc. to GlucoTrack, Inc. occurred on March 28, 2022.
What is Glucotrack, Inc.'s fiscal year end?
Glucotrack, Inc.'s fiscal year end is December 31.
Filing Stats: 1,860 words · 7 min read · ~6 pages · Grade level 8.6 · Accepted 2025-02-04 09:20:12
Key Financial Figures
- $0.001 — f the Company's common stock, par value $0.001 per share (the "Common Stock"). The Rev
Filing Documents
- form8-k.htm (8-K) — 94KB
- ex3-1.htm (EX-3.1) — 13KB
- ex99-1.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 11KB
- 0001493152-25-004793.txt ( ) — 320KB
- gctk-20250203.xsd (EX-101.SCH) — 3KB
- gctk-20250203_lab.xml (EX-101.LAB) — 33KB
- gctk-20250203_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On February 4, 2025, the Company issued a press release (the "Press Release") announcing the completion of the Company's first in-human clinical study of its continuous blood glucose monitor. The Press Release is furnished as Exhibit 99.1 and incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference into any filing with the Securities and Exchange Commission, except as expressly set forth by specific reference in such a filing. Item 8.01 Other Events The table below sets forth the impact of the Reverse Stock Split on the Company's net loss per common share - basic and diluted weighted average common shares outstanding - basic and diluted and shares issued and outstanding, for the years ended December 31, 2023 and 2022 the three months ended March 31, 2024 and 2023, the three and six months ended June 30, 2024 and 2023, and the three and nine months ended September 30, 2024 and 2023. In thousands of US Dollars (except stock and per stock amounts) PRE SPLIT (1) POST SPLIT (1) YEAR ENDED DECEMBER 31, YEAR ENDED DECEMBER 31, 2023 2022 2023 2022 Comprehensive net loss $ (7,098 ) $ (4,412 ) $ (7,098 ) $ (4,412 ) Net loss per common share - basic $ (0.38 ) $ (0.29 ) $ (34.19 ) $ (28.51 ) Net loss per common share - diluted $ (0.38 ) $ (0.29 ) $ (34.19 ) $ (28.51 ) Weighted average common shares outstanding - basic 20,760,266 15,474,600 207,603 154,746 Weighted average common shares outstanding - diluted 20,760,266 15,474,600 207,603 154,746 Common stock outstanding at year end 20,892,193 15,550,730 208,922 155,008 In thousands of US Dollars (except stock and per stock amounts) PRE SPLIT (2) POST SPLIT (2) 3 MONTHS END
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 4, 2025 GLUCOTRACK, INC. By: /s/ Paul Goode Name: Paul Goode Title: Chief Executive Officer